Key Points
- CEO Grigorios Siokas purchased 56,080 shares on Nov. 21 at $0.68 (total $38,134.40) and made additional buys on Nov. 19–20, bringing his stake to 6,327,893 shares (a 0.89% increase, ~ $4.3M), as disclosed in an SEC filing.
- Cosmos Health is a small-cap (market cap ~$24.06M) with negative EPS (last quarter EPS -$0.17, missing estimates) and a consensus analyst rating of "Sell"
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas purchased 56,080 shares of Cosmos Health stock in a transaction dated Friday, November 21st. The stock was acquired at an average price of $0.68 per share, for a total transaction of $38,134.40. Following the completion of the acquisition, the chief executive officer owned 6,327,893 shares of the company's stock, valued at approximately $4,302,967.24. This trade represents a 0.89% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Grigorios Siokas also recently made the following trade(s):
- On Thursday, November 20th, Grigorios Siokas acquired 51,315 shares of Cosmos Health stock. The shares were acquired at an average price of $0.62 per share, with a total value of $31,815.30.
- On Wednesday, November 19th, Grigorios Siokas acquired 61,614 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $40,049.10.
Cosmos Health Stock Up 1.7%
NASDAQ:COSM opened at $0.69 on Tuesday. The company has a market cap of $24.06 million, a price-to-earnings ratio of -0.92 and a beta of 5.32. Cosmos Health Inc. has a twelve month low of $0.28 and a twelve month high of $1.32. The company has a current ratio of 0.99, a quick ratio of 0.84 and a debt-to-equity ratio of 0.25. The stock has a fifty day simple moving average of $0.93 and a 200-day simple moving average of $0.72.
Cosmos Health (NASDAQ:COSM - Get Free Report) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.16). Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%.The company had revenue of $17.11 million during the quarter, compared to the consensus estimate of $16.40 million. Analysts anticipate that Cosmos Health Inc. will post -0.78 EPS for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen upgraded Cosmos Health to a "hold" rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Sell".
View Our Latest Analysis on COSM
Institutional Investors Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC increased its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 225,507 shares of the company's stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.61% of the company's stock.
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
